The results are very encouraging news for Amgen and Repatha, which is in a head-to-head marketing battle with Sanofi and Regeneron’s Praluent to be the dominant PCSK9 inhibitor. Both drugs have ...

The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

Amgen) are the two mAbs currently approved by the FDA; both received approval in 2015. [Repatha package insert; 1a; 23a; Praluent package insert;1a;6b] The activity of PCSK9 can also be inhibited ...

AstraZeneca’s experimental pill has shown promise in reducing “bad” cholesterol, raising expectations for more convenient alternatives in treatment options. AstraZenca is testing a once-daily PCSK9 ...

Among these PCSK9-targeting therapies is Novartis’s Leqvio (inclisiran), Amgen’s Repatha (evolocumab), and Regeneron’s ...

"We've had PCSK9 inhibitors on the market in the United States for 10 years," said investigator Michael Koren, MD, a cardiologist and CEO of the ENCORE Research Group in Jacksonville, Florida.

Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibitors lower cholesterol and risk for heart disease, but barriers to access exist. A pharmacist ...